Availability Of An Investigational Drug For Severe Cushing’s Syndrome On a Compassionate Use Basis
December, 2011
We would like to make patients aware that mifepristone, an investigational drug that blocks the action of cortisol and is being developed by Corcept Therapeutics Incorporated, is now available on a compassionate use basis for eligible patients in the United States with Cushing’s syndrome who have no other treatment options.
Under this compassionate use program, the FDA allows seriously ill patients who lack satisfactory alternative treatment options to use an investigation